Home › Ischemic Stroke › NCT03347786

Verapamil for Neuroprotection in Stroke

Intraarterial Verapamil for Neuroprotection in Ischemic Stroke

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Written informed consent
* 18 years of age and over
* Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
* Candidate for mechanical thrombectomy procedure
* Onset of symptoms less than 8 hours
* Measurable neurologic deficit (NIHSS ≥4)
* Willingness to follow up with rehabilitation therapy
* Anticipated life expectancy of at least 3 months

Exclusion Criteria:

* Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
* Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min)
* Thrombocytopenia (platelet count \<75,000/mm3)
* History of intolerance to verapamil
* Previous functional disability (modified Rankin \> 1)
* Severe stroke (NIHSS\>22)
* Stuporous or comatose
* Unlikely to be available for 90 day follow-up

About the study

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

What is being tested

• 10 mg Intra-arterial Verapamil (drug)
• 20 mg Intra-arterial Verapamil (drug)

Sponsor: Global Neurosciences Institute · Participants: 60 · Started: Apr 20, 2017

Contact the study team

Official record on ClinicalTrials.gov — NCT03347786

Locations in the U.S.

Conditions

• Ischemic Stroke

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.